Establishing a preclinical decision framework for drugs
Preclinical safety programs often follow a standard template to determine off-target effects.
However, some molecule classes and targets may raise other concerns. A well-informed, well-structured workflow needs to be thorough both in terms of information sources and methodology.
Using a theoretical drug indicated for metastatic renal cancer, in this paper, Dr. William B. Mattes examines the preclinical workflow for pharmaceutical safety analysis, including a study of:
- The regulatory documentation for the target
- Preclinical and clinical safety findings for approved drugs
- Safety concerns raised in regulatory documents
- Strategies used for similar drugs and their success
Read the case study.
To access the complimentary case study 'Establishing a preclinical decision framework for drugs', please fill in the form below.
Innovation and Performance: What's Data Got to Do With It?
Pharmaceutical companies must uphold patient safety and manage pharmacovigilance regulatory compliance risks. How are industry leaders driving business performance amidst big data? What are the common challenges and bottlenecks?
Professional Services Case Study: Compliant Monitoring of Adverse Events
A review of how Elsevier's R&D Solution Professional Services helped a pharmaceutical company become more compliant with literature screening requirements.
Elsevier's R&D Solutions for Pharmacovigilance
Promote efficiency and organizational compliance by centralizing the discovery of adverse event information and automating information monitoring and triage in a scalable environment.
Learn more about QUOSA PV
Contact a QUOSA PV expert
Make more informed drug development decisions on safety and efficacy, risk assessments and mitigation, and study designs by providing researchers with searchable FDA/EMA drug approval documents and comparative drug safety data.
Learn more about PharmaPendium
Contact a PharmaPendium expert